These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15773274)

  • 21. Annual cost of stable coronary artery disease in France: A modeling study.
    Caruba T; Chevreul K; Zarca K; Cadier B; Juillière Y; Dubourg O; Sabatier B; Danchin N
    Arch Cardiovasc Dis; 2015 Nov; 108(11):576-88. PubMed ID: 26433733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous treatment of multivessel coronary disease in the drug eluting stent era: comparison of bare-metal stents, drug-eluting stents and a mixed approach in a large multicentre registry.
    Varani E; Saia F; Balducelli M; Guastaroba P; Marrozzini C; Tarantino F; Passerini F; Sangiorgio P; Percoco G; Grilli R; Marzocchi A; Maresta A
    EuroIntervention; 2007 Feb; 2(4):474-80. PubMed ID: 19755287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts.
    Lee MS; Shah AP; Aragon J; Jamali A; Dohad S; Kar S; Makkar RR
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):507-11. PubMed ID: 16270361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry).
    Frutkin AD; Lindsey JB; Mehta SK; House JA; Spertus JA; Cohen DJ; Rumsfeld JS; Marso SP;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):614-21. PubMed ID: 19628183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients undergoing multivessel percutaneous coronary intervention using sirolimus-eluting stents: a report from the e-SELECT registry.
    Cuculi F; Banning AP; Abizaid A; Bartorelli AL; Baux AC; Dzavík V; Ellis S; Gao R; Holmes D; Jeong MH; Legrand V; Neumann FJ; Nyakern M; Spaulding C; Stoll HP; Worthley S; Urban P;
    EuroIntervention; 2011 Dec; 7(8):962-8. PubMed ID: 22157482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug-eluting stents: from the results of clinical studies to economic simulation models in the Italian reality].
    Sangiorgi G; Rodamni P; Airoldi F; Colombo A
    Ital Heart J Suppl; 2005 Mar; 6(3):145-56. PubMed ID: 15875500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease.
    Hannan EL; Samadashvili Z; Walford G; Holmes DR; Jacobs AK; Stamato NJ; Venditti FJ; Sharma S; King SB
    JACC Cardiovasc Interv; 2010 Jan; 3(1):22-31. PubMed ID: 20129564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry.
    Brilakis ES; Wang TY; Rao SV; Banerjee S; Goldman S; Shunk K; Kar B; Holmes DR; Dai D; Chin CT; Harding TM; Roe MT
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1068-73. PubMed ID: 20965466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple vessel stenting for triple vessel coronary disease.
    Villegas B; Morice MC; Hernandez S; Choussat R; Dumas P; Lefevre T; Louvard Y; Loubeyre C; Fajadet J; Marco J
    J Invasive Cardiol; 2002 Jan; 14(1):1-5. PubMed ID: 11773686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
    Shishehbor MH; Topol EJ; Mukherjee D; Hu T; Cohen DJ; Stone GW; McClure R; Roffi M; Moliterno DJ;
    Am J Cardiol; 2006 Jun; 97(11):1585-90. PubMed ID: 16728219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome.
    Harskamp RE; Kuijt WJ; Damman P; Beijk MA; Grundeken MJ; Woudstra P; Tijssen JG; de Winter RJ
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):203-9. PubMed ID: 22508617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stenting of unprotected left main coronary artery in patients with low preoperative risk of coronary artery bypass grafting.
    Dudek D; Heba G; Giszterowicz D; Rzeszutko Ł; Legutko J; Bartuś S; Chyrchel M; Dubiel JS
    Kardiol Pol; 2006 Sep; 64(9):929-36; discussion 937-8. PubMed ID: 17054024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison.
    Ijsselmuiden AJ; Ezechiels J; Westendorp IC; Tijssen JG; Kiemeneij F; Slagboom T; van der Wieken R; Tangelder G; Serruys PW; Laarman G
    Am Heart J; 2004 Sep; 148(3):467-74. PubMed ID: 15389234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial.
    Kapur A; Hall RJ; Malik IS; Qureshi AC; Butts J; de Belder M; Baumbach A; Angelini G; de Belder A; Oldroyd KG; Flather M; Roughton M; Nihoyannopoulos P; Bagger JP; Morgan K; Beatt KJ
    J Am Coll Cardiol; 2010 Feb; 55(5):432-40. PubMed ID: 20117456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Health-economic modeling on the use of drug-eluting stents versus coronary artery bypass graft surgery in coronary heart disease].
    Gorenoi V; Dintsios CM; Schönermark MP; Hagen A
    Herz; 2009 May; 34(3):231-9. PubMed ID: 19444408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic appraisal of the angioplasty procedures performed in 2004 in a high-volume diagnostic and interventional cardiology unit.
    Manari A; Costa E; Scivales A; Ponzi P; Di Stasi F; Guiducci V; Pignatelli G; Giacometti P
    J Cardiovasc Med (Hagerstown); 2007 Oct; 8(10):792-8. PubMed ID: 17885516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease.
    Lee MS; Yang T; Dhoot J; Iqbal Z; Liao H
    Am J Cardiol; 2010 Jun; 105(11):1540-4. PubMed ID: 20494658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.